Nycomed sells 70% drugs stake
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.NYCOMED AMERSHAM, the world's leading maker of medical imaging products, yesterday agreed to sell a 70 per cent stake in its pharmaceuticals business to Nordic Capital, a Swedish private equity investor, for pounds 275m in order to focus on its main businesses.
The company said it would use the proceeds to cut its debt by about half, giving it more scope to expand its business in diagnostic products.
Nycomed, formed by the 1997 merger of Norway's Nycomed ASA and Amersham International, said last year it planned to sell its pharmaceuticals unit, Nycomed Pharma, which generated 19 per cent of its pounds 1.39bn sales in 1998.
Analysts said the price was low but the sale was needed. "There is slight disappointment about the price, but it gets them out of a non- core business so they can focus on core areas,'' said Ian Smith, an analyst with Lehman Brothers.
Nycomed shares rose by 2.5p to 504.5p yesterday.
Nordic Capital and Nycomed said they had formed a new company to acquire the drug unit, with Nycomed paying pounds 21m for a 30 per cent stake.
With a pounds 44m loan Nycomed will make to the new company, the transaction is worth pounds 340m.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments